A worrying thought - Could there be a connection between encapsulating peritoneal sclerosis, tamoxifen and calciphylaxis?

Nephrology Dialysis Transplantation

Volumn 21, Issue 10, 2006, Pages 2975-2978

  Korzets, Asher ^a,b   Ori, Yaacov ^a,b   Zevin, Dina ^a,b   Chagnac, Avry ^a,b   Herman, Michal ^a,b   Rozen Zvi, Benaya ^a,b   Gafter, Uzi ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Calciphylaxis; Dialysis; Encapsulating peritoneal sclerosis; Tamoxifen

Indexed keywords

ANTIBIOTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; PAMIDRONIC ACID; PREDNISONE; TAMOXIFEN; VINCRISTINE;

ABDOMINAL PAIN; ADULT; ANEMIA; ARTERY CALCIFICATION; ARTICLE; ASCITES; B CELL LYMPHOMA; BONE SCINTISCANNING; CALCINOSIS; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DRUG RESPONSE; ENCAPSULATING PERITONEAL SCLEROSIS; ESOPHAGITIS; FEMALE; GANGRENE; GASTRECTOMY BILLROTH II; GENITAL PAIN; HEMODIALYSIS; HUMAN; HYPERBILIRUBINEMIA; HYPOALBUMINEMIA; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MALE; PERITONEAL DISEASE; PRIORITY JOURNAL; STOMACH LYMPHOMA; TOTAL PARENTERAL NUTRITION; URETHRA DISEASE; VATER PAPILLOTOMY; VOMITING; WEIGHT REDUCTION;

CALCIPHYLAXIS; FATAL OUTCOME; FEMALE; HUMANS; MALE; MIDDLE AGED; PERITONEAL DISEASES; PERITONEUM; RENAL DIALYSIS; SCLEROSIS; TAMOXIFEN;

EID: 33749635463     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl372     Document Type: Article

References (25)

1. Nakamoto H. Encapsulating peritoneal sclerosis - a clinician's approach to diagnosis and medical treatment. Perit Dial Int 2005; 25 [Suppl 4]: S30-S38
2. Summers AM, Clancy MJ, Syed F et al. Single-center experience of encapsulating peritoneal sclerosis in patients on peritoneal dialysis for end-stage renal failure. Kidney Int 2005; 68: 2381-2388
3. Rigby RJ, Hawley CM. Sclerosing peritonitis: The experience in Australia. Nephrol Dial Transplant 1998; 13: 154-159
4. Kawanishi H, Harada Y, Sakikubo E et al. Surgical treatment for sclerosising encapsulating peritonitis. Adv Perit Dial 2000; 16: 252-256
5. del Peso G, Bajo MA, Gil F et al. Clinical experience with tamoxifen in peritoneal fibrosing syndromes. Adv Perit Dial 2003; 19: 32-35
6. van Bommel EF, Hendriksz TR, Huiskes AW, Zeegers AG. Brief communication: Tamoxifen therapy for nonmalignant retroperitoneal fibrosis. Ann Intern Med 2006; 144: 101-106
7. Cosman F, Baz-Hecht M, Cushman M et al. Short-term effects of estrogen, tamoxifen and raloxifene on hemostasis: A randomized-controlled study and review of the literature. Thromb Res 2005; 116: 1-13
8. Essary LR, Wick MR. Cutaneous calciphylaxis. An under-recognized clinicopathologic entity. Am J Clin Pathol 2000; 113: 280-287
9. Korzets A, Korzets Z et al. Sclerosing peritonitis. Possible early diagnosis by computerized tomography of the abdomen. Am J Nephrol 1988; 8: 143-146
10. Ragaz J, Coldman AJ. Survival impact of adjuvant tamoxifen on competing causes of mortality in breast cancer survivors, with analysis of mortality from contralateral breast cancer, cardiovascular events, endometrial cancer and thromboembolic episodes. J Clin Oncol 1998; 16: 2018-2024
11. Cuzick J, Powles T, Veronesi U et al. Overview of the main outcomes in breast cancer prevention trials. Lancet 2003; 361: 296-300
12. Benson JR, Wakefield LM, Baum M, Colletta AA. Synthesis and secretion of transforming growth factor beta isoforms by primary cultures of human breast tumor fibroblasts in vitro and their modulation by tamoxifen. Br J Cancer 1996; 74: 352-358
13. Border WA, Noble NA. Transforming growth factor β in tissue fibrosis. New Engl J Med 1994; 331: 1286-1292
14. Miyazaki M, Yuzawa Y. The role of peritoneal fibrosis in encapsulating peritoneal sclerosis. Perit Dial Int 2005; 25 [Suppl 4]: S48-S56
15. Weitz IC, Israel VK, Liebman HA. Tamoxifen associated venous thrombosis and activated protein C resistance due to factor V Leiden. Cancer 1996; 79: 2024-2027
16. Meier CR, Jick H. Tamoxifen and risk of idiopathic venous thromboembolism. Br J Clin Pharmacol 1998; 45: 608-612
17. Cushman M, Costantino JP, Bovill EG et al. Effect of tamoxifen on venous thrombosis risk factors in women without cancer: The Breast Cancer Prevention Trial. Br J Haematol 2003; 120: 109-116
18. Vitseva O, Flockhart DA, Jin Y, Varghese S, Freedman JE. The effects of tamoxifen and its metabolites on platelet function and release of reactive oxygen intermediates. J Pharmacol Exp Therap 2005; 312: 1144-1150
19. Budisavijevic MN, Cheek D, Ploth DW. Calciphylaxis in chronic renal failure. J Am Soc Nephrol 1996; 7: 978-982
20. Metha RL, Scott G, Sloand JA, Francis CW. Skin necrosis associated with acquired protein C deficiency in patients with renal failure and calciphylaxis. Am J Med 1990; 88: 252-257
21. Rostaing L, El Feki S, Delisle M-B et al. Calciphylaxis in a chronic hemodialysis patient with protein S deficiency. Am J Nephrol 1995; 15: 524-527
22. Goldsmith DJA. Calciphylaxis, thrombotic diathesis and defects in coagulation regulation. Nephrol Dial Transplant 1997; 12: 1082-1083
23. Basic-Jukic N, Kes P. Does sclerosing peritonitis induce MIA syndrome and generalized sclerosis? Perit Dial Int 2005; 25: 608-610
24. Kawaguchi Y, Saito A, Kawanishi H et al. Recommendations on the management of encapsulating peritoneal sclerosis in Japan, 2005: diagnosis, predictive markers, treatment and preventive measures. Perit Dial Int 2005; 25 [Suppl 4]: S83-S95
25. Eltoum MA, Wright S, Atchley J, Mason JC. Four consecutive cases of peritoneal dialysis-related encapsulating peritoneal sclerosis treated successfully with tamoxifen. Perit Dial Int 2006; 26: 203-206